Crossbow Therapeutics develops T-Cell Receptor mimetic antibodies that precisely target tumor-specific peptides presented by Major Histocompatibility Complex (MHC), enhancing the efficacy of antibody therapies against cancer. Their technology addresses the challenge of reaching previously inaccessible cancer antigens, thereby broadening the therapeutic potential of immunotherapy for patients.
Funding
$80M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PVFounders
Product
Problem
Current antibody therapies are limited by their inability to target intracellular cancer antigens, restricting their effectiveness against a broad range of tumors. Many cancer antigens reside inside cells, inaccessible to traditional antibody-based treatments.
Solution
Crossbow Therapeutics is developing T-Cell Receptor (TCR) mimetic antibodies that can precisely target tumor-specific peptides presented by Major Histocompatibility Complex (MHC) molecules. This approach enables the development of antibody therapies that can reach previously inaccessible intracellular cancer antigens, expanding the therapeutic potential of immunotherapy. Crossbow's T-Bolt molecules are designed to strike tumor cells with accuracy and potency. The company identifies and validates promising cancer antigens, creates high-quality TCR-mimetics using a proprietary technology engine, and develops innovative products such as T-cell engagers. These antibodies are incorporated into immunotherapies, optimizing manufacturability and potency while minimizing tumor resistance.
Target Audience
Crossbow's primary target audience includes cancer patients and the medical community seeking more effective and precise cancer therapies.
Features
- Proprietary technology engine for creating highly potent and accurate TCR-mimetic antibodies
- Ability to target tumor-specific peptides presented by MHC, mimicking T-Cell Receptors (TCRs)
- Development of T-Cell engagers and other immunotherapies
- Optimization of manufacturability and potency
- Minimization of tumor resistance
- Identification, validation, and prioritization of promising cancer antigens